Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 100 | 1 | 101 | +2 |
| Shares | 16.9M | 1.53K | 14.5M | −2.40M (−14.3%) |
| Value | $36.6M | $3.33K | $33.7M | −$2.88M (−7.9%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 452,757 | $1.05M | 0.00% |
| Citadel Advisors LLC | 334,227 | $778.7K | 0.00% |
| STRS Ohio | 296,100 | $689.9K | 0.00% |
| Hillsdale Investment Management Inc. | 185,711 | $432.7K | 0.01% |
| Millennium Management LLC | 171,535 | $399.7K | 0.00% |
| Bailard, Inc. | 61,100 | $142.4K | 0.00% |
| State of Wyoming | 59,179 | $137.9K | 0.01% |
| Winton Group Ltd | 56,001 | $130.5K | 0.00% |
| Franklin Resources Inc | 41,314 | $96.3K | 0.00% |
| Point72 Asset Management, L.P. | 25,566 | $59.6K | 0.00% |
| Walleye Capital LLC | 19,839 | $46.2K | 0.00% |
| Two Sigma Securities, LLC | 17,795 | $41.5K | 0.00% |
| Ieq Capital, LLC | 13,774 | $32.1K | 0.00% |
| MCF Advisors LLC | 10,000 | $23.3K | 0.00% |
| Geneos Wealth Management Inc. | 800 | $1.86K | 0.00% |
| Farther Finance Advisors, LLC | 108 | $253 | 0.00% |
| SJS Investment Consulting Inc. | 30 | $70 | 0.00% |
| Caitong International Asset Management Co., Ltd | 3 | $7 | 0.00% |
Sold out (16)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Mak Capital One LLC | 3,544,139 | $7.69M |
| Prospera Financial Services Inc | 418,570 | $908.3K |
| Opaleye Management Inc. | 340,000 | $737.8K |
| Connor, Clark & Lunn Investment Management Ltd. | 207,275 | $449.8K |
| Round Rock Advisors, LLC | 192,080 | $416.8K |
| Evergreen Capital Management LLC | 171,338 | $371.8K |
| Diametric Capital, LP | 124,195 | $269.5K |
| Virtu Financial LLC | 67,893 | $147.0K |
| Manufacturers Life Insurance Company, The | 19,528 | $42.4K |
| ProShare Advisors LLC | 10,589 | $23.0K |
| LPL Financial LLC | 10,291 | $22.3K |
| Baader Bank INC | 10,046 | $14.4K |
| C M Bidwell & Associates Ltd | 236 | $512 |
| Root Financial Partners, LLC | 128 | $278 |
| Northwestern Mutual Wealth Management Co | 100 | $217 |
| MAI Capital Management | 29 | $63 |
Not filed for Q2 2026 yet (1)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| CWM, LLC | 1,534 | $3.33K |